#LCSM Chat Topic 5/3/18:  What Defines a “Quality” #LungCancer Treatment Center?  Thoughts from the Frontline

Our topic for the #LCSM Tweet Chat on Thursday, May 3rd (5 PM Pacific/8 PM Eastern) is “What Defines a “Quality” #LungCancer Treatment Center?  Thoughts from the Frontline.” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD). Recently the Centers for Medicaid and Medicare Services (CMS) announced it would cover next-generation sequencing (NGS) for US patients with stage III or IV lung cancer when ordered by a physician and performed in a CLIA-certified laboratory.  This decision makes broad genomic testing to available to many more patients.  Having increased access to… Read More

#LCSM Chat Topic 22-Feb-2018: Lung cancer research–Why we need it and how we can get more

“Cancer research” is a broad term that encompasses everything from basic bench science, to translational research on patient-derived tumor specimens, to clinical trials, to studies on patient centered outcomes.  While it is obvious to all of us in the lung cancer community that research is critical to improving patient outcomes, lung cancer remains underfunded compared to other common cancers. Several different mechanisms exist to fund cancer research, including private philanthropy, Big Pharma, not-for-profit cancer research and advocacy groups, and government organizations including the DOD and NIH/NCI among others. Given funding imbalances, it… Read More

#LCSM Chat Topic 2/8/18: Right to Try Laws and CIMAVax

  “Right to Try” laws for people with a terminal illness have been a longstanding issue and are currently on the books in 38 states. The lack of a federal law supporting this concept was touched upon in President Trump’s State of the Union address last week. On its face, offering liberal options that permit these patients to try any still investigational agent that has completed phase I testing seems like a benefit to patients who may be desperate for options. A couple of arguments in favor of it are available here:… Read More